Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Adnexal Mass: early-phase trial registry

1 of 3 indexed Adnexal Mass trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Adnexal Mass: 3 US clinical trials tracked, 1 recruiting.

Adnexal Mass is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, running 1 of these trials.

Enrollment posture brief

Registry condition adnexal-mass

OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Adnexal Mass (this)33%
Open-enrollment share among volume-matched conditions near Adnexal Mass

Adnexal Mass lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adnexal Mass on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adnexal Mass is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Named interventions

Most-linked intervention names on Adnexal Mass records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Method 3: Indocyanine green dye Drug
1 trials
Method 2: Indocyanine green dye Drug
1 trials
Method 1: Indocyanine green dye Drug
1 trials
Contrast-Enhanced Subharmonic Ultrasound Imaging Procedure
1 trials
Blood Collection Diagnostic test
1 trials
Vaginal Fluid Collection Diagnostic test
1 trials
Perflutren Lipid Microspheres Drug
1 trials

US sites by state

Facility locations filed on Adnexal Mass trials. A trial with sites in several states counts in each.

New York 2 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New Jersey 1 trials
North Dakota 1 trials
Mississippi 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adnexal Mass page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adnexal Mass condition card totals 3 registered trials; most-linked intervention Method 3: Indocyanine green dye; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.